Review

Early onset facioscapulohumeral dystrophy – a systematic review using individual patient data

Rianne J.M. Goselink [a,*], Nicol C. Voermans [a], Kees Okkersen [a], Oebele F. Brouwer [b], George W. Padberg [a], Ana Nikolic [c], Rossella Tupler [c,d], Malgorzata Dorobek [e], Jean K. Mah [f], Baziel G.M. van Engelen [a], Tim H.A. Schreuder [a,1], Corrie E. Erasmus [a,1]

[a] Department of Neurology, Donders Centre for Medical Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
[b] Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
[c] Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
[d] Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, USA
[e] Department of Neurology, Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland
[f] Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Abstract

Infantile or early onset is estimated to occur in around 10% of all facioscapulohumeral dystrophy (FSHD) patients. Although small series of early onset FSHD patients have been reported, comprehensive data on the clinical phenotype is missing. We performed a systematic literature search on the clinical features of early onset FSHD comprising a total of 43 articles with individual data on 227 patients. Additional data from four cohorts was provided by the authors. Mean age at reporting was 18.8 years, and 40% of patients were wheelchair-dependent at that age. Half of the patients had systemic features, including hearing loss (40%), retinal abnormalities (37%) and developmental delay (8%). We found an inverse correlation between repeat size and disease severity, similar to adult-onset FSHD. De novo FSHD1 mutations were more prevalent than in adult-onset FSHD. Compared to adult FSHD, our findings indicate that early onset FSHD is overall characterized by a more severe muscle phenotype and a higher prevalence of systemic features. However, similar as in adults, a significant clinical heterogeneity was observed. Based on this, we consider early onset FSHD to be on the severe end of the FSHD disease spectrum. We found natural history studies and treatment studies to be very scarce in early onset FSHD, therefore longitudinal studies are needed to improve prognostication, clinical management and trial-readiness.
© 2017 Elsevier B.V. All rights reserved.

Keywords: Facioscapulohumeral dystrophy; Early onset; Infantile FSHD

1. Introduction

Facioscapulohumeral dystrophy (FSHD) is one of the most frequent hereditary muscular diseases with an estimated prevalence of 5–13 in 100,000 [1,2]. In 3–21% of patients the symptoms start at an early age [3,4]. Currently, two genetically distinct types of FSHD, called FSHD1 and FSHD2, are known. In both types, inefficient epigenetic repression of the retrogene DUX4 plays a key role in the pathogenesis [5,6]. FSHD1 accounts for 95% of all patients and almost all early onset cases

[7], it is associated with contraction of the D4Z4-repeat at chromosome 4q35 in combination with a disease-permissive 4qA allele [8,9]. In the general population, the number of D4Z4 repeat units varies between 11 to more than 100, while patients with FSHD1 have only 1–10 repeat units. There is a roughly inverse correlation between repeat size and disease severity; most patients with short repeats have a severe disease phenotype [10,11].

Historically, *infantile FSHD* was considered a distinct disease based on clinical onset before the age of two years (Brooke criteria, 1977 [12]). This concept evolved to *early onset FSHD* and was regarded a subgroup of FSHD, defined by signs or symptoms of facial weakness before the age of 5 and signs or symptoms of scapular weakness before the age of 10 (Brouwer criteria, 1994 [13]). Whereas the typical, classic form of FSHD is characterized by slowly progressive, often

---

* Corresponding author. Department of Neurology, Donders Centre for Brain, Cognition and Behaviour, Radboud University Medical Center, Reinier Postlaan 4, 6525 GC Nijmegen, The Netherlands.
E-mail address: rianne.goselink@radboudumc.nl (R.J.M. Goselink).
[1] Authors contributed equally.

asymmetrical muscle weakness of facial- and shoulder muscles starting in the second decade of life [3,14], the subgroup of early onset FSHD patients is characterized by severe muscle weakness, faster disease progression and systemic features. These systemic features include epilepsy, mental retardation, hearing loss, retinal vasculopathy, spinal deformities, respiratory problems and cardiac arrhythmias [3,13,15–19]. It should be noted that clinical variability in terms of age at onset and disease severity is typical of FSHD. Age at onset ranges from birth to 70 years of age and disease severity may vary from asymptomatic carriers to patients with severe muscle weakness causing functional dependence.

Our current understanding of disease severity, systemic features and prognosis in early onset FSHD is based on small case-series. Consequently, many questions about the clinical phenotype and natural history of early onset FSHD remain unanswered, thus limiting evidence based clinical management. Here, we systematically review the literature using individual patient data to gain insight into the clinical spectrum of early onset FSHD. The ultimate goals are to improve recognition and understanding of early onset FSHD and to advance clinical management.

2. Methods

2.1. Search strategy

We searched Embase (index period 1970–2016) and PubMed (index period 1970–2016) for articles reporting early onset FSHD cases (Supplementary Appendix A). We applied a sensitive search strategy using search terms as described in Table 1. Additional studies of potential interest were searched via cross-referencing.

2.2. Eligibility screening

We included articles presenting empirical data on early onset FSHD patients. We excluded conference abstracts, posters, publications not reporting original data (*e.g.* reviews, book chapters) and studies not reported in English. Articles of potential interest were screened on the basis of title and abstract after which full-text evaluation was performed on the remaining articles (R.G.).

After article selection, two authors (R.G. and T.S.) independently assessed the eligibility of individual patients and disagreements were resolved by consensus. We included patients who fulfilled the criteria by Brooke (signs of FSHD

within the first two years of life [12]) or the criteria by Brouwer (signs or symptoms of facial weakness before the age of five and signs or symptoms of shoulder weakness before the age of ten [13]). Cases were excluded if a concomitant, neuromuscular disease was present.

2.3. Data-extraction

For every reported patient, we collected the following parameters: demographics (sex, race, age at onset, age at examination), clinical characteristics (clinical severity, age at wheelchair dependency, muscle involvement pattern), systemic features (developmental abnormalities, perinatal complications, mental capacity, hearing loss, retinal abnormalities, epilepsy, spinal deformities, respiratory problems and cardiac problems), and genetic characteristics (hereditary pattern and repeat length). For assessment of the clinical severity the Clinical Severity Score by Ricci ('Ricci score' [11]) was used. We obtained the score from the article or estimated it based on the clinical description. The age corrected CSS, correcting for age at examination published by van Overveld [20] was also calculated. The authors from the two largest cohorts and two other cohorts [4,13,21,22] supplied additional individual patient data.

2.4. Statistics

Descriptive statistics were performed for continuous and categorical data as appropriate. We performed exploratory statistical analyses to assess relations between variables of demography, disease severity, systemic features and genetic parameters. We used linear regression if the dependent variable was continuous and logistical regression for dichotomous variables. Correction for multiple testing was not applied and our analyses should be considered as hypothesis generating [23]. To this end, we only considered relations with $p < 0.05$ of potential interest. All statistical analyses were performed using IBM SPSS (version 22.0, IBM Corp, Armonk, NY).

3. Results

3.1. Search and selection results

The combined searches yielded 953 records, of which 303 were duplicates, leaving a total of 650 unique articles (Figure 1). This resulted in 43 articles including 1683 patients of which 227 are early-onset FSHD patients (Table 2).

3.2. Clinical description of early onset FSHD

Mean age at assessment was 18.8 years (range 2–72 years, SD 11.9 years). Symptoms started at a mean age of 2.8 years (range 0–5 years, SD 2.8 years). 56/227 of patients (25%) showed symptoms in the first year of life, mainly facial weakness resulting in feeding difficulties and less frequently inadequate eye closure. Perinatal complications (prematurity, low birth weight, and dysmorphic features) were reported in five cases (5/99, 5%) and none was related to muscle weakness of the child.

Table 1
Search terms used in pubmed and embase.

| FSHD	AND	case OR patient OR series
OR		OR
facioscapulohumeral dystrophy		child OR infant OR infantile OR early-onset OR severe
		OR
OR		epilepsy OR mental retardation OR hearing loss
landouzy		OR
		Coats OR retinal OR teleangiectasis

Fig. 1. Flow-chart of study and case selection.

At assessment, the mean Ricci-score was 7 out of 10 (SD 2.6) and the mean age-corrected clinical severity score 1040 (SD 800). In general, the pattern of muscle involvement was similar to the classical FSHD phenotype with facial, scapulohumeral, axial and peroneal muscle weakness. Forty percent of patients were wheelchair dependent; the average age of wheelchair dependency was 17 years (SD 7.8) (Figure 2). Mean duration from age at onset to wheelchair dependency was 14.6 years (SD 7.8, range 4–37 years). Skeletal deformities were present in 70% of patients and included lumbar hyperlordosis (51%), kyphoscoliosis (9%) pectus excavatum (2%) and multiple deformities (8%).

Approximately 50% of early onset FSHD patients had systemic features (hearing loss, vision loss, epilepsy, intellectual disability, pulmonary abnormalities, and cardiac abnormalities) (Table 3). Of these, approximately two thirds had a single systemic feature, and the other third had multiple systemic features. Clinical hearing loss, predominantly high frequency loss without need of hearing aids was the most frequent feature (40%), and 7% of patients had subclinical hearing loss at auditory testing. Clinical vision loss was described in 13 out of 227 patients (6%) and signs of retinopathy were detected in 41 of 112 tested patients (37%). Spirometry results were available for 112 patients, and decreased percentage predicted forced vital capacity was detected in approximately one third. Eighteen out of the total 227 patients were on assisted ventilation at the time of assessment. Cardiac abnormalities were found in 9% of the 93 conducted electrocardiograms in 93 patients, consisting of incomplete right bundle branch blocks (4 patients), right ventricular hypertrophy (2 patients), right atrial hypertrophy (1 patient), and 1st degree atrioventricular block (1 patient). Epilepsy was present in 18 patients (8%); 5 patients had localization-related (focal) epilepsy, 2 patients had generalized epilepsy and 11 patients had unclassified epileptic seizures.

Genetic confirmation of the diagnosis FSHD was present in 171 of 227 reported cases. For 93 patients, DNA from parents was available. In 68 out of these 93 families, a 'de novo' mutation was found (73%). The mean repeat length was 14.2 Kb (SD 4.8, range 9–31). Eleven out of 93 patients were mosaic (12%).

3.3. Associations with disease severity

A complete overview of all calculated associations between disease variables is shown in Supplementary Appendix B. We here focus on the clinically most relevant associations. A shorter D4Z4 repeat length was associated with a higher age-corrected clinical severity score (standardized beta -0.202,

Table 2
Summary of included articles.

First Author[ref]	Year	Country	Study type	#iFSHD	#cases	Selection criteria	Genetic confirmation
Hanson [24]	1971	USA	Case-series	3	3	iFSHD	
Carroll [25]	1979	USA	Case-series	11	11	iFSHD	
Taylor [26]	1982	USA	Case-series	2	2	iFSHD + retinopathy	
Wulff [27]	1982	USA	Case-report	1	1	iFSHD	
McGarry [28]	1983	USA	Case-report	2	2	iFSHD	
Meyerson [29]	1984	USA	Case-report	2	3	iFSHD + hearing loss	
Gieron [30]	1985	USA	Case-report	3	4	iFSHD	
Gurwin [31]	1985	GBR	Case-report	3	4	iFSHD	
Korf [32]	1985	USA	Case-series	6	6	iFSHD + hearing loss	
Bailey [33]	1986	USA	Case-report	1	8	iFSHD	
Voit [34]	1986	DEU	Case-series	7	10	iFSHD + hearing loss	
Yasukochi [35]	1988	JPN	Case-series	2	2	iFSHD + retinopathy	
Shapiro [36]	1991	USA	Case-series	9	9	iFSHD	
Kamata [37]	1993	JPN	Case-report	1	1	iFSHD	
Brouwer [13]*	1994	NLD	Case-series	6	6	iFSHD	†
Jardine [38]	1994	GBR/DEU	Case-series	19	27	iFSHD	†
Brouwer [21]*	1995	NLD	Case-series	4	4	iFSHD	
Je Hyeon [39]	1995	JPN	Case-report	1	1	iFSHD	†
Nakagawa [40]	1996	JPN	Case-report	1	2	iFSHD	†
Nakagawa [40]	1997	JPN	Population cohort	7	42	FSHD	†
Okinaga [41]	1997	JPN	Case-series	2	3	iFSHD	†
Funakoshi [15]	1998	JPN	Population cohort	20	127	FSHD	‡
Miura [42]	1998	JPN	Case-series	2	2	iFSHD	†
Lapena [43]	2001	AUS	Case-series	1	1	Vocal cord paralysis	‡
Dorobek [44]	2004	POL	Case-report	1	2	iFSHD	‡
Wohlgemuth [45]	2004	NLD	Case-series	4	10	FSHD + assisted ventilation	‡
Felice [46]	2005	USA	Case-report	2	3	iFSHD	‡
Bindoff [47]	2006	NOR	Case-series	2	2	iFSHD	‡
Klinge [16]	2006	GBR	Case-series	7	7	iFSHD	‡
Saito [48]	2007	JPN	Case-report	1	1	iFSHD	
Shields [49]	2007	USA	Case-report	1	1	iFSHD	‡
Kolski [50]	2008	CAN	Case-report	1	1	iFSHD	‡
Kriswalsky [51]	2008	USA	Case-report	1	1	iFSHD	‡
Trevisan [17]	2008	ITA	Case-series	5	7	iFSHD + 10-13Kb	‡
Lee [52]	2009	JPN	Case-report	1	1	iFSHD	‡
Grosso [53]	2011	ITA	Case-report	3	7	iFSHD	‡
Sakellariou [54]	2012	GRE	Population cohort	3	127	FSHD	‡
Wang [55]	2012	TWN	Population cohort	7	24	FSHD	‡
Chen [19]	2013	TWN	Case-series	9	9	iFSHD + 10-13Kb	‡
Statland [56]	2013	USA	Case-series	3	10	FSHD + retinopathy	‡
Kana [57]	2013	JPN	Case-report	1	1	iFSHD	‡
Dorobek [4]*	2015	POL	Population cohort	22	103	FSHD	‡
Nikolic [22]*	2016	ITA	Population cohort	36	850	FSHD + 1–3 D4Z4 RU	‡

* Additional data provided by the authors.
† Southern blot p13E.
‡ Double digested EcoRI/BlnI.

p = 0.019), more wheelchair dependency (OR 0.178, p = 0.035), more hearing loss (OR 0.254, p = 0.002), and more epilepsy (OR 0.205, p = 0.014). An earlier age at onset is correlated with more frequently hearing loss (OR 0.827, p = 0.001) and hearing loss is correlated with vision loss (OR 6.370, p = 0.007) and intellectual disability (OR 2.272, p = 0.028). Intellectual disability is associated with epilepsy (OR 80.0, p = 0.000). Wheelchair dependency is associated with skeletal deformities (OR 1.855, p = 0.034) and with assisted ventilation (OR 4.839, p = 0.000).

4. Discussion

Based on data from 227 early onset FSHD cases, we conclude that early onset FSHD is on the severe end of the FSHD spectrum. The genetic defect, the distribution pattern of muscular weakness and the type of systemic features are similar to the classical FSHD phenotype. Early onset FSHD distinguishes itself from the adult-onset patients by a more severe muscle weakness, more rapid progression and more frequently occurring systemic features. Some systemic features (cognitive disability, epilepsy) are only associated with early onset FSHD.

Early onset FSHD patients demonstrate high CSS scores (mean 7.35, SD 2.6; median 7, IQR 5.5–10) and age corrected CSS (mean 1008, SD 645; median 842, IQR 571–1273). Of note, standard deviations and interquartile ranges are indicative of substantial clinical variation that is characteristic of FSHD. Also, these severity scores have not been validated in early onset

Fig. 2. Age at loss of ambulation from subgroup of wheelchair dependent patients (n = 78). Mean age is 17 years (standard deviation 7.8 years).

FSHD populations. However, the percentage of early onset patients being wheelchair-dependent (40%) versus that in the general FSHD population (6.4% [58]) underscores the severe muscle weakness in the former group. This is reflected by the high prevalence of spinal deformities, especially lumbar hyperlordosis, indicative of early axial weakness. Respiratory

Table 3
Patient characteristics of published early onset FSHD cases (n = 227).

Demographics	
Age at reporting (yrs)	18.8 ± 11.9
Male sex – no.	103 (45%)
African background – no./total no.*	2/227 (1%)
Asian background – no./total no.*	56/227 (25%)
Caucasian background – no./total no.*	169/227 (74%)
Clinical history	
Perinatal complications – no./total no.	5/99 (5%)
Age at onset – mean (yrs)†	2.8 ± 2.8
Clinical severity score (CSS) – mean ± SD	7.4 ± 2.6
Age corrected CSS – mean ± SD	1042 ± 800
Wheelchair dependency – no./total no.	87/217 (40%)
Age at wheelchair dependency (yrs)	17.2 ± 7.8
Systemic symptoms	
Hearing loss – no./total	91/227 (40%)
Subclinical hearing loss – no./total no.	15/210 (7%)
Retinopathy – no./total no.	41/112 (37%)
Vision loss – no./total no.	13/227 (6%)
Epilepsy – no./total no.	18/227 (8%)
Developmental delay- no./total no.	35/227 (15%)
ECG abnormalities – no./total no.	8/93 (9%)
Spinal deformities – no./total no.	105/152 (70%)
Decreased forced vital capacity (%FVC) - no./total no.	37/121 (31%)
Assisted ventilation – no./total no.	18/227 (8%)
Genetic characteristics	
Repeat length – mean (range, SD)	14.2 Kb (9–31 Kb, 4.8)
De novo mutations – no./total no. (%)	68/93 (73%)
Mosaic inheritance– no./total no. (%)	11/93 (12%)

* Based on study location.
† as reported by the parents/caregivers.

abnormalities are associated with spinal deformities in this and other studies. Therefore, the higher prevalence of assisted ventilation in our early onset population (8%) versus the general FSHD populations (0–7%) is not surprising [45,59,60]. The latter findings underline the need for regular pulmonary monitoring by spirometry in early onset FSHD patients [61]. In addition, we confirm the progressive nature of FSHD in the early onset population (Supplementary Appendix B; wheelchair dependency and respiratory failure increase with age).

Furthermore, systemic features occur frequently in early onset FSHD. The most frequent systemic feature in this population was hearing loss (40%). It was characterized by sensorineural loss of preferentially higher frequencies of limited severity, and hearing aids are usually not necessary. The frequency of hearing loss in the general FSHD population is unclear due to widely varying frequencies (ranging from no association to 64% in selected populations, mean 15% [18,61–64]. The high frequency of hearing loss underscores the need for screening hearing function by audiometry, especially during speech development.

We found a lower prevalence of subclinical retinopathy (37%) than reported in literature (50–75%) [64,65], This is probably due to suboptimal screening methods (no fluorescence angiography). Another explanation might be the later onset of retinal abnormalities. We did find a higher rate of clinical vision loss compared to the general FSHD population (6% vs. 0.8%–1.7% [56,64]). Of note, this percentage is significantly higher than previously reported.

Electrocardiographic anomalies were present in 9% of early onset FSHD patients, a prevalence roughly corresponding to literature on the general FSHD population (albeit being very heterogenic (range 0–60% [61,66–68], for an overview see Tawil et al [61].) and consisted of arrhythmia and other minor abnormalities. The clinical consequences of arrhythmia seem to be minor since none of the patients required pacemaker intervention. Interestingly, we found electrocardiographic changes mainly in patients of Asian origin. This geographic difference has not been previously reported and deserves attention in future studies, especially because we also found significantly different prevalence of mental impairment and epilepsy between patients from Caucasian and Asian descent.

We found a high percentage of 'de novo' mutations in the early onset FSHD patients: 73% versus 30% in the general FSHD population [69]. Presumably, severe muscular weakness limits procreation in early onset FSHD patients. Of note, we did not find significant differences between early onset patients with 'de novo' mutations versus those with a positive family history. An association between repeat length and the age-corrected disease severity score previously reported in the general FSHD population [70], could be confirmed in the early onset FSHD patients.

4.1. Limitations and future directions

Besides its strength of a multinational systematic review of individual patient data on a large number of patients, this study has a number of limitations. Case reports and case series bear the potential of publication and selection bias, which might lead to

overestimation of the severity of disease and prevalence of systemic features. Inclusion criteria in some of the included studies, such as selection of patients with short repeat lengths or those with hearing difficulties, increases such bias. Moreover, utilizing the criteria for early onset/infantile FSHD by Brooke and Brouwer, which address motor symptoms, leads to the possible exclusion of patients with atypical (i.e. non-motor) onset of FSHD; we are aware of cases with a retinal vasculopathy presentation [47,71]. Due to the cross-sectional nature of the current review and the studies included herein, we remain unaware on the longitudinal course of early onset FSHD. The average age at assessment was approximately 18 years. Considering the progressive nature of the disease and the fact that these patients are on the severe end of the FSHD spectrum, progressive handicap and complications could be expected. The nature of our data and the limitations discussed above underline the need for well designed, larger longitudinal cohort studies in early onset FSHD. Such studies are underway and have the potential of improving the prognostication and classification of early onset FSHD patients [72,73]. For now, classification on the basis of age of onset has practical utility both in clinical practice and clinical trials; the authors therefore recommend using the criteria by Brouwer to define early-onset FSHD.

Acknowledgements

Appendix: Supplementary material

Supplementary data to this article can be found online at doi: 10.1016/j.nmd.2017.09.007.

References

[1] Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 2014;83:1056–9.

[2] Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet 2009;75:550–5.

[3] Padberg GW. Facioscapulohumeral dystrophy. [PhD thesis]. Leiden: Leiden University 1982. https://openaccess.leidenuniv.nl/handle/1887/25818.

[4] Dorobek M, van der Maarel SM, Lemmers RJ, Ryniewicz B, Kabzińska D, Frants RR, et al. Early-onset facioscapulohumeral muscular dystrophy type 1 with some atypical features. J Child Neurol 2015;30:580–7.

[5] Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010;329:1650–3.

[6] Tawil R, van der Maarel SM, Tapscott SJ. Facioscapulohumeral dystrophy: the path to consensus on pathophysiology. Skelet Muscle 2014;4:12.

[7] Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG. What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol 2016;16:201–7.

[8] Wijmenga C, Frants RR, Brouwer OF, Moerer P, Weber JL, Padberg GW. Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 1990;336:651–3.

[9] de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, Frants RR, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 2009;30:1449–59.

[10] Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, McDermott M, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol 1996;39:744–8.

[11] Ricci E, Galluzzi G, Deidda G, Cacurri S, Colantoni L, Merico B, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999;45:751–7.

[12] Brooke MH. Clinical examination of patients with neuromuscular disease. Adv Neurol 1977;17:25–39.

[13] Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 1994;51:387–94.

[14] Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006;34:1–15.

[15] Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology 1998;50:1791–4.

[16] Klinge L, Eagle M, Haggerty ID, Roberts CE, Straub V, Bushby KM. Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2006;16:553–8.

[17] Trevisan CP, Pastorello E, Tomelleri G, Vercelli L, Bruno C, Scapolan S, et al. Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions. Eur J Neurol 2008;15:1353–8.

[18] Lutz KL, Holte L, Kliethermes SA, Stephan C, Mathews KD. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology 2013;81:1374–7.

[19] Chen TH, Lai YH, Lee PL, Hsu JH, Goto K, Hayashi YK, et al. Infantile facioscapulohumeral muscular dystrophy revisited: expansion of clinical phenotypes in patients with a very short EcoRI fragment. Neuromuscul Disord 2013;23:298–305.

[20] van Overveld PG, Enthoven L, Ricci E, Rossi M, Felicetti L, Jeanpierre M, et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 2005;58:569–76.

[21] Brouwer OF, Padberg GW, Bakker E, Wijmenga C, Frants RR. Early onset facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl 1995;S67–72.

[22] Nikolic A, Ricci G, Sera F, Bucci E, Govi M, Mele F, et al. Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 1–3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry. BMJ Open 2016;6:e007798.

[23] Streiner DL, Norman GR. Correction for multiple testing: is there a resolution? Chest 2011;140:16–18.

[24] Hanson PA, Rowland LP. Mobius syndrome and facioscapulohumeral muscular dystrophy. Arch Neurol 1971;24:31–9.

[25] Carroll JE, Brooke MH. Infantile Facioscapulohumeral Dystrophy. In: Peroneal atrophies and related disorders. 1979. p. 305–19.

[26] Taylor DA, Carroll JE, Smith ME, Johnson MO, Johnston GP, Brooke MH. Facioscapulohumeral dystrophy associated with hearing loss and Coats syndrome. Ann Neurol 1982;12:395–8.

[27] Wulff JD, Lin JT, Kepes JJ. Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome. Ann Neurol 1982;12:398–401.

[28] McGarry J, Garg B, Silbert S. Death in childhood due to facio-scapulo-humeral dystrophy. Acta Neurol Scand 1983;68:61–3.

[29] Meyerson MD, Lewis E, Ill K. Facioscapulohumeral muscular dystrophy and accompanying hearing loss. Arch Otolaryngol 1984;110:261–6.

[30] Gieron MA, Korthals JK, Kousseff BG. Facioscapulohumeral dystrophy with cochlear hearing loss and tortuosity of retinal vessels. Am J Med Genet 1985;22:143–7.

[31] Gurwin EB, Fitzsimons RB, Sehmi KS, Bird AC. Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness. Arch Ophthalmol 1985;103:1695–700.

[32] Korf BR, Bresnan MJ, Shapiro F, Sotrel A, Abroms IF. Facioscapulohumeral dystrophy presenting in infancy with facial diplegia and sensorineural deafness. Ann Neurol 1985;17:513–6.

[33] Bailey RO, Marzulo DC, Hans MB. Infantile facioscapulohumeral muscular dystrophy: new observations. Acta Neurol Scand 1986;74:51–8.

[34] Voit T, Lamprecht A, Lenard HG, Goebel HH. Hearing loss in facioscapulohumeral dystrophy. Eur J Pediatr 1986;145:280–5.

[35] Yasukohchi S, Yagi Y, Akabane T, Terauchi A, Tamagawa K, Mizuno Y. Facioscapulohumeral dystrophy associated with sensorineural hearing loss, tortuosity of retinal arterioles, and an early onset and rapid progression of respiratory failure. Brain Dev 1988;10:319–24.

[36] Shapiro F, Specht L, Korf BR. Locomotor problems in infantile facioscapulohumeral muscular dystrophy. Retrospective study of 9 patients. Acta Orthop Scand 1991;62:367–71.

[37] Kamata T, Miyajima H, Shimizu T, Fujimoto M, Takahashi Y, Kaneko E. Facioscapulohumeral syndrome with sensorineural hearing loss and abnormality of retinal vessels. Intern Med 1993;32:678–80.

[38] Jardine PE, Koch MC, Lunt PW, et al. De novo facioscapulohumeral muscular dystrophy defined by DNA probe p13E-11 (D4F104S1). Arch Dis Child 1994;71:221–7.

[39] Je Hyeon L, Goto K, Sahashi K, Nonaka I, Matsuda C, Arahata K. Cloning and mapping of a very short (10-kb) EcoRI fragment associated with facioscapulohumeral muscular dystrophy (FSHD). Muscle Nerve 1995;18:S27–31.

[40] Nakagawa M, Higuchi I, Yoshidome H, et al. Familial facioscapulohumeral muscular dystrophy: phenotypic diversity and genetic abnormality. Acta Neurol Scand 1996;93:189–92.

[41] Okinaga A, Matsuoka T, Umeda J, et al. Early-onset facioscapulohumeral muscular dystrophy: two case reports. Brain Dev 1997;19:563–7.

[42] Miura K, Kumagai T, Matsumoto A, et al. Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy. Neuropediatrics 1998;29:239–41.

[43] Lapena JF Jr, Berkowitz RG. Neuromuscular disorders presenting as congenital bilateral vocal cord paralysis. Annals of Otology, Rhinology and Laryngology 2001;110:952–5.

[44] Dorobek M, Kabzinska D. A severe case of facioscapulohumeral muscular dystrophy (FSHD) with some uncommon clinical features and a short 4q35 fragment. Eur J Paediatr Neurol 2004;8:313–16.

[45] Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004;63:176–8.

[46] Felice KJ, Jones JM, Conway SR. Facioscapulohumeral dystrophy presenting as infantile facial diplegia and late-onset limb-girdle myopathy in members of the same family. Muscle Nerve 2005;32:368–72.

[47] Bindoff LA, Mjellem N, Sommerfelt K, Krossnes BK, Roberts F, Krohn J, et al. Severe fascioscapulohumeral muscular dystrophy presenting with Coats' disease and mental retardation. Neuromuscul Disord 2006;16:559–63.

[48] Saito Y, Miyashita S, Yokoyama A, et al. Facioscapulohumeral muscular dystrophy with severe mental retardation and epilepsy. Brain Dev 2007;29:231–3.

[49] Shields CL, Zahler J, Falk N, et al. Neovascular glaucoma from advanced coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol 2007;125:840–2.

[50] Kolski HK, Leonard NJ, Lemmers RJLF, Bamforth JS. Atypical facet of Mobius syndrome: association with facioscapulohumeral muscular dystrophy. Muscle Nerve 2008;37:526–9.

[51] Kriwalsky MS, Deschauer M, Eckert AW, Schubert J, Zierz S. Orthognathic surgery in a case of infantile facioscapulohumeral muscular dystrophy with macroglossia. Oral and Maxillofacial Surgery 2008;12:195–8.

[52] Lee CS, Kang SJ, Hwang CJ, et al. Early-onset facioscapulohumeral muscular dystrophy - Significance of pelvic extensors in sagittal spinal imbalance. J Pediatr Orthop B 2009;18:325–9.

[53] Grosso S, Mostardini R, Di Bartolo RM, Balestri P, Verrotti A. Epilepsy, speech delay, and mental retardation in facioscapulohumeral muscular dystrophy. Eur J Paediatr Neurol 2011;15:456–60.

[54] Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. Neuromuscul Disord 2012;22:339–49.

[55] Wang CH, Leung M, Liang WC, Hsieh TJ, Chen TH, Jong YJ. Correlation between muscle involvement, phenotype and D4Z4 fragment size in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2012;22:331–8.

[56] Statland JM, Sacconi S, Farmakidis C, Donlin-Smith CM, Chung M, Tawil R. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology 2013;80:1247–50.

[57] Kana M, Hideki H, Madoka M, et al. Autopsy case of early onset of facioscapulohumeral dystrophy. Neuropathology 2013;33(3):359.

[58] Statland JM, Tawil R. Risk of functional impairment in facioscapulohumeral muscular dystrophy. Muscle Nerve 2014;49:520–7.

[59] Santos DB, Boussaid G, Stojkovic T, Orlikowski D, Letilly N, Behin A, et al. Respiratory muscle dysfunction in facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2015;25:632–9.

[60] Moreira S, Wood L, Smith D, Marini-Bettolo C, Guglieri M, McMacken G, et al. Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol 2017;264:1271–80.

[61] Tawil R, Kissel JT, Heatwole C, Pandya S, Gronseth G, Benatar M. Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology and the practice issues review panel of the american association of neuromuscular & electrodiagnostic medicine. Neurology 2015;85:357–64.

[62] Rogers MT, Zhao F, Harper PS, Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2002;12:358–65.

[63] Trevisan CP, Pastorello E, Ermani M, Angelini C, Tomelleri G, Tonin P, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol 2008;13:1–6.

[64] Padberg GW, Brouwer OF, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl 1995;S73-80.

[65] Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987;110(Pt 3):631–48.

[66] Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol 2006;56:1–5.

[67] De Visser M, De Voogt WG, La Riviere GV. The heart in becker muscular dystrophy, facioscapulohumeral dystrophy, and bethlem myopathy. Muscle Nerve 1992;15:591–6.

[68] Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990;15:292–9.

[69] Zatz M, Marie SK, Passos-Bueno MR, Vainzof M, Campiotto S, Cerqueira A, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 1995;56:99–105.

[70] Lemmers RJ, Goeman JJ, van der Vliet PJ, van Nieuwenhuizen MP, Balog J, Vos-Versteeg M, et al. Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Hum Mol Genet 2015;24:659–69.

[71] Ganesh A, Kaliki S, Shields CL. Coats-like retinopathy in an infant with preclinical facioscapulohumeral dystrophy. J AAPOS 2012;16:204–6.

[72] Duong T, Eagle M, Feng J, Mah J. Baseline characteristics of the CINRG infantile facioscapulohumeral muscular dystrophy cohort. Neuromuscul Disord 2015;25:S215.

[73] Goselink RJ, Schreuder TH, Mul K, Voermans NC, Pelsma M, de Groot IJ, et al. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurol 2016;16:138.